Prostatype
Commercial- Indications
- Prostate cancer
Company intelligence / Profile preview
Prostatype® is a clinically validated prognostic gene expression test for men with localized prostate cancer. It combines the expression profiles of three stem cell genes from biopsy tissue with clinical parameters to generate a personalized risk score ("P-score") for aggressive disease. The test has been validated in multiple studies involving approximately 2500 patients and is CE-marked. It helps guide treatment decisions, particularly regarding active surveillance versus intervention, aiming to reduce over-treatment and under-treatment. The company is currently seeking Medicare reimbursement approval in the US.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Prostatype Genomics.